Enhancing glioblastoma cytotoxicity through encapsulating O6-benzylguanine and temozolomide in PEGylated liposomal nanocarrier: an in vitro study
3 Biotech · 2024-11 · 14 (11)
DOI: 10.1007/s13205-024-04123-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift 3 Biotech, online erschienen am 23.10.2024. Verfasst von Manasa Manjunath Hegde und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Biology & Toxicology, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, India. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Science and Technology, Ministry of Science and Technology, India, Manipal Academy of Higher Education, Manipal.
Abstract (Originalsprache)
Glioblastoma (GBM) (grade IV glioma) is the most fatal brain tumor, with a median survival of just 14 months despite current treatments. Temozolomide (TMZ), an alkylating agent used with radiation, faces challenges such as systemic toxicity, poor absorption, and drug resistance. To enhance TMZ effectiveness, we developed poly(ethylene glycol) (PEG) liposomes co-loaded with TMZ and O6-benzylguanine (O6-BG) for targeted glioma therapy. These liposomes, prepared using the thin-layer hydration method, had an average size of 146.33 ± 6.75 nm and a negative zeta potential (−49.6 ± 3.1 mV). Drug release was slower at physiological pH, with 66.84 ± 4.62% of TMZ and 69.70 ± 2.88% of O6-BG released, indicating stability at physiological conditions. The liposomes showed significantly higher cellular uptake (p < 0.05) than the free dye. The dual drug-loaded liposomes exhibited superior cytotoxicity against U87 glioma cells, with a lower IC 50 value (3.99µg/mL) than the free drug combination, demonstrating enhanced anticancer efficacy. The liposome formulation induced higher apoptosis (19.42 ± 3.5%) by causing sub-G0/G1 cell cycle arrest. The novelty of our study lies in co-encapsulating TMZ and O6-BG within PEGylated liposomes, effectively overcoming drug resistance and improving targeted delivery for glioma treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Biology & Toxicology, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, India.
- Advance Centre for Treatment Research and Education in Cancer, Tata Memorial Centre & Homi Bhaba National Institute, Navi Mumbai, India.
- Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India.
- Department of Radiation Oncology, Advanced Centre for Treatment Research Education in Cancer, Tata Memorial Centre & Homi Bhaba National Institute, Navi Mumbai, India.
- Manipal School of Life Sciences & Director-Research, Manipal Academy of Higher Education, Manipal, India.
ORCID-Profile: B S Satish Rao
Förderung
- Department of Science and Technology, Ministry of Science and Technology, India
- Manipal Academy of Higher Education, Manipal
Zitieren
APA
Hegde, M. M., Palkar, P., Mutalik, S. P., Mutalik, S., Goda, J. S., & Rao, B. S. S. (2024). Enhancing glioblastoma cytotoxicity through encapsulating O6-benzylguanine and temozolomide in PEGylated liposomal nanocarrier: an in vitro study. 3 Biotech, 14(11). https://doi.org/10.1007/s13205-024-04123-2
Vancouver
Hegde MM, Palkar P, Mutalik SP, Mutalik S, Goda JS, Rao BSS. Enhancing glioblastoma cytotoxicity through encapsulating O6-benzylguanine and temozolomide in PEGylated liposomal nanocarrier: an in vitro study. 3 Biotech. 2024;14(11). doi:10.1007/s13205-024-04123-2
BibTeX
@article{Hegde2024,
author = {Hegde, Manasa Manjunath and Palkar, Pranoti and Mutalik, Sadhana P and Mutalik, Srinivas and Goda, Jayant Sastri and Rao, B S Satish},
title = {Enhancing glioblastoma cytotoxicity through encapsulating O6-benzylguanine and temozolomide in PEGylated liposomal nanocarrier: an in vitro study},
journal = {3 Biotech},
year = {2024},
volume = {14},
number = {11},
doi = {10.1007/s13205-024-04123-2}
}
EUVIMED